Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cornelius E. Golding Joins Retrophin, Inc.'s Board of Directors
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB: RTRX) today announced that it has elected Cornelius ("Neal") E. Golding to its Board of Directors, effective October 1, 2013 . Mr. Golding will also serve as Chairman of the Audit Committee. His appointment brings the Company's Board to four
View HTML
Toggle Summary Dr. Alvin Shih Departing Retrophin to Lead Biotechnology Start-Up
SAN DIEGO , Oct. 06, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih , M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr.
View HTML
Toggle Summary Jeffrey Paley, MD, Joins Retrophin Inc.'s Board of Directors
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (OTCQB:RTRX) today announced that it has appointed Jeffrey Paley , MD to its Board of Directors, effective November 15, 2013 . This latest appointment brings the Company's Board to five members. Commenting on today's news, Martin Shkreli , Founder,
View HTML
Toggle Summary John A. Orwin Joins Retrophin Board of Directors
SAN DIEGO , March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company's Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc.
View HTML
Toggle Summary Ligand Licenses DARA Program to Retrophin
Potential for over $75 million in milestone payments to Ligand plus royalties Retrophin plans to develop DARA for rare nephropathies and other indications
View HTML
Toggle Summary Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid
U.S. filing for primary biliary cholangitis indication anticipated in 2017
View HTML
Toggle Summary Retrophin Agrees to Sell Priority Review Voucher to Sanofi
Proceeds of $245 million over two years SAN DIEGO --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher ("Pediatric PRV") to Sanofi (NYSE:SNY). Retrophin received the Pediatric PRV when Cholbam™ was approved
View HTML
Toggle Summary Retrophin and St. Jude Children’s Research Hospital to Collaborate on Rare Disease Research Program
Program led by Dr. Suzanne Jackowski will test Retrophin replacement therapy library for treatment of PKAN, a rare neurodegenerative disease
View HTML
Toggle Summary Retrophin Announces $80 Million Term Loan and Convertible Note Issuance
NEW YORK --(BUSINESS WIRE)-- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has signed a binding commitment on a $40 million senior secured term loan facility, provided by Athyrium Capital Management . The term loan will mature in 2018, have an interest rate of LIBOR plus 10% (with a LIBOR
View HTML
Toggle Summary Retrophin Announces Acceptance of Four RE-024 Abstracts for Presentation at the 20th International Congress of Parkinson's Disease and Movement Disorders
SAN DIEGO , March 24, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced that four abstracts related to the development of RE-024, the company's novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), have been accepted for poster
View HTML